StockData
Myomo, Inc. logo

Myomo, Inc. (MYO) company profile

MYONYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3030% below fair value
$0.88−0.04 (-4.23%)

Close on Nov 18, 2026Market cap $34.85MP/E –Yield –

About Myomo

Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842

Myomo is a wearable medical robotics company that develops and markets myoelectric-controlled upper limb orthoses, operating as a single business segment. Its core offering is the MyoPro product line, which includes custom-fabricated rigid arm braces that use non-invasive electromyography sensors to detect weak muscle signals and power movement in partially paralyzed upper limbs. The company serves adults and adolescents with neuromuscular conditions and upper limb paralysis resulting from stroke, brachial plexus injuries, spinal cord trauma, and other neurological disorders. Customers access these devices through direct billing to insurers, orthotics and prosthetics providers, and healthcare institutions.

The company is headquartered in Burlington, Massachusetts. It markets and distributes products across the United States, with devices ordered by more than 130 Veterans Administration facilities. Internationally, the firm holds medical device licensing in Canada, maintains European Union market authorization via CE mark compliance, and has distribution relationships with orthotics and prosthetics partners across the United Kingdom, Germany, Italy, Denmark, and Australia.

Summary of the business section of Myomo's latest annual report, written by StockData.

Company profile

Company

Legal name
Myomo, Inc.
Founded
2004
Headquarters
Boston, MA
Address
137 Portland Street, 4th Floor 02114
Phone
(617) 996-9058
Website
myomo.com
Employees
184, Dec 31, 2024
Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Marcum LLP, New York, NY. USA

Stock & identifiers

Ticker
MYO
Exchange
NYSE
IPO date
Jun 12, 2017
Shares outstanding
40M, Jul 31, 2026
Public float
$62.36M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-30 reverse, Jan 31, 2020
SEC CIK
1369290
CUSIP
62857J201
ISIN
US62857J2015
FIGI
BBG002B0JJV6
Share class FIGI
BBG002B0JJW5
LEI
549300G63SSKC2EGLN41
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Paul R. GudonisChief Executive Officer, Director1,514,292
David A. HenryChief Financial Officer549,862
Harry KovelmanChief Medical Officer89,889
Mary-Katherine Hale McClureChief Commericial Officer275,000
Micah MitchellChief Commercial Officer152,297
Milton Mayo MorrisDirector208,391
Joseph M. Manko Jr.Director2,388,479
William J. FebboDirector123,704
Thomas F. KirkDirector772,569
Thomas Aloysius Crowley Jr.Director154,931
Heather C. GetzDirector210,458

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.20M-$348.55K$649.02K$178–
FY2024$1.24M$1.51M$739.64K$1259–
FY2023$663.90K$2.12M$478.64K$980–
FY2022$526.04K$179.60K$352.85K$7–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Paul R. Gudonis
Chief Executive Officer
$375.00K$600.07K$208.61K$17.50K$1.20M-3%
David A. Henry
Chief Financial Officer
$283.90K$291.37K$97.48K$17.50K$690.24K-12%
Harry Kovelman
Chief Medical Officer
$283.66K$238.49K$78.31K$7.34K$607.80K-13%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2024, we employed a total of 184 full time employees and 1 part time employee.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?